Musculoskeletal Imaging

Which Imaging Study Is Best for Staging Extrapulmonary Metastasis in Musculoskeletal Tumors?

·
Which Imaging Study Is Best for Staging Extrapulmonary Metastasis in Musculoskeletal Tumors?

A 45-year-old patient presents with a newly biopsied high-grade sarcoma of the thigh. Following local imaging with MRI, the multidisciplinary tumor board must now determine the full extent of the disease to finalize a treatment plan. The critical question is whether the cancer has spread to distant sites beyond the lungs, such as other bones, lymph nodes, or visceral organs. Choosing the right whole-body imaging modality is essential for accurate staging and will fundamentally guide therapy. This article details the clinical workflow for evaluating extrapulmonary metastasis in a patient with a known malignant or aggressive primary musculoskeletal tumor. Based on the American College of Radiology (ACR) Appropriateness Criteria, whole-body Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) is rated Usually appropriate as the recommended study for this clinical scenario.

## Who Fits This Clinical Scenario for Staging Extrapulmonary Metastasis?

This guidance applies to a specific point in the patient journey: the initial staging phase after a malignant or aggressive primary musculoskeletal tumor has been confirmed by biopsy. The primary tumor’s local extent has typically already been evaluated (often with MRI), and the specific goal now is a systemic search for distant disease outside of the chest.

Inclusion criteria for this workflow:

  • Patients with a new, biopsy-proven diagnosis of a high-grade or aggressive primary musculoskeletal malignancy (e.g., osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, undifferentiated pleomorphic sarcoma).
  • The clinical question is specifically the detection of extrapulmonary metastases (i.e., in bone, lymph nodes, or visceral organs).
  • This evaluation is part of the initial, pre-treatment staging process.

This workflow does NOT apply to:

  • Evaluation for pulmonary metastases only: This represents a different clinical question. While PET/CT can detect lung nodules, a dedicated high-resolution chest CT is the standard for evaluating the lungs. See the ACR variant on staging for pulmonary metastasis.
  • Post-treatment surveillance: Patients who have completed their initial therapy and are now being monitored for recurrence follow different surveillance protocols.
  • Evaluation of local recurrence: If suspicion is for tumor regrowth at the primary site after treatment, a dedicated MRI of that area is typically the first step.
  • Low-grade or benign tumors: For tumors with a very low likelihood of metastasis (e.g., low-grade chondrosarcoma, benign bone tumors), systemic staging is generally not indicated.

## What Diagnoses Are You Working Up When Staging for Distant Disease?

When ordering a whole-body staging study, the goal is to definitively confirm or exclude the presence of metastatic disease, which would classify the patient as having Stage IV cancer. The key sites of concern for most aggressive musculoskeletal tumors, beyond the lungs, are bone, lymph nodes, and other soft tissues.

Skeletal Metastases
For many primary bone sarcomas like osteosarcoma and Ewing sarcoma, the most common site of distant spread after the lungs is the skeleton. These can manifest as “skip” lesions within the same bone as the primary tumor or as distant osseous metastases in other parts of the body. Identifying these is critical, as their presence drastically changes the prognosis and treatment approach, often necessitating more intensive systemic chemotherapy.

Lymph Node Metastases
While sarcomas are classically thought to spread hematogenously (through the blood), certain histologic subtypes have a significant propensity for lymphatic spread. These include rhabdomyosarcoma, synovial sarcoma, epithelioid sarcoma, and clear cell sarcoma. Detecting nodal involvement is crucial for planning radiation therapy fields and may prompt consideration for lymph node dissection.

Visceral Metastases (Non-pulmonary)
Less commonly, aggressive sarcomas can spread to other organs like the liver, adrenal glands, brain, or distant soft tissues. The detection of visceral disease carries significant prognostic weight and confirms the need for aggressive systemic therapy. A whole-body survey is essential to uncover these otherwise clinically silent deposits of disease.

## Why Is Whole-Body FDG-PET/CT Usually Appropriate for Staging Extrapulmonary Metastases?

The ACR designates FDG-PET/CT whole body as Usually appropriate because it provides a comprehensive, single-session evaluation that combines metabolic and anatomic information, making it highly effective for detecting occult metastatic disease throughout the body.

The rationale for this recommendation is multifaceted. Malignant cells in high-grade sarcomas are typically hypermetabolic, leading to intense uptake of the radiotracer FDG. The PET component detects these areas of high metabolic activity with high sensitivity, while the fused CT component provides the precise anatomic location of the uptake, whether it’s in a bone, lymph node, or organ. This dual capability makes it superior to other modalities for a global assessment.

Comparison to Alternative Studies

  • Bone Scan (whole body): Rated May be appropriate. A technetium-99m bone scan is sensitive for detecting osteoblastic (bone-forming) skeletal metastases. However, it is less sensitive for purely lytic (bone-destroying) or marrow-based disease, which can be missed. Crucially, it provides no information about metastatic disease in lymph nodes or soft tissues, making it an incomplete staging study for this scenario. FDG-PET/CT evaluates all of these sites simultaneously.
  • MRI whole body without IV contrast: Rated May be appropriate (Disagreement). Whole-body MRI offers excellent soft-tissue contrast and is highly sensitive for detecting bone marrow infiltration. However, the examination is long, more susceptible to motion artifact, and its utility for evaluating visceral organs or lymph nodes without intravenous contrast is debated among experts, leading to the “Disagreement” qualifier. It also lacks the specific metabolic information that PET provides.

Radiation and Practical Considerations
FDG-PET/CT involves a significant radiation dose (ACR Relative Radiation Level ☢☢☢☢, 10-30 mSv for adults). This exposure is considered justified in the context of staging a life-threatening malignancy, where the results will directly and profoundly impact treatment decisions. The CT portion is often performed without IV contrast for staging, as the primary goal is anatomic localization of PET findings, not detailed soft-tissue characterization.

## What’s the Next Step After a Staging FDG-PET/CT?

The results of the staging FDG-PET/CT create a critical branch point in the patient’s management plan. The downstream workflow depends directly on whether distant disease is identified.

  • If the study is positive for distant metastases: The identification of avid lesions consistent with metastatic disease upstages the patient to Stage IV. If a solitary or unusual site of metastasis is found, a biopsy may be performed to histologically confirm the finding, as this confirmation solidifies a shift from curative-intent local therapy to a palliative or systemic-therapy-first approach. The patient’s treatment will be primarily guided by medical and radiation oncology, focusing on systemic chemotherapy.
  • If the study is negative for distant metastases: A negative PET/CT, in conjunction with negative chest imaging, indicates localized disease. The patient can proceed with a curative-intent treatment plan focused on the primary tumor. This typically involves a combination of neoadjuvant or adjuvant chemotherapy and definitive local control with surgery and/or radiation therapy. The patient then transitions to a structured surveillance program to monitor for future recurrence.
  • If the study shows indeterminate findings: FDG-PET/CT is not perfectly specific; inflammation, infection, and even brown fat can cause FDG uptake. If an equivocal finding is reported, the next step is targeted problem-solving. This may involve a dedicated diagnostic study of the area of concern (e.g., a contrast-enhanced MRI or CT) or a percutaneous biopsy to clarify the nature of the finding before committing to a final treatment plan.

## Common Pitfalls to Avoid in Staging and When to Escalate

Accurate staging requires careful planning and interpretation. Avoiding common errors can prevent misdiagnosis and ensure the patient receives the most appropriate care.

1. Ignoring Patient Preparation: Hyperglycemia at the time of FDG injection can competitively inhibit tumor uptake, potentially leading to a false-negative scan. Always ensure the patient has been fasting appropriately and that blood glucose is within an acceptable range before the radiotracer is administered.
2. Misinterpreting Physiologic Uptake: Normal, high-level FDG uptake occurs in the brain, myocardium, and urinary system. Physiologic muscle uptake or brown fat activity can also be confounding. Relying on an experienced nuclear medicine physician or radiologist is key to distinguishing these from true pathology.
3. Substituting PET/CT for Local Staging: While the primary tumor will be avid on PET/CT, this study does not replace a dedicated, high-resolution MRI of the primary site. MRI remains the gold standard for defining the tumor’s local extent and its relationship to adjacent neurovascular structures, which is essential for surgical planning.

If staging results are complex, contradictory, or do not fit the clinical picture, the case must be discussed at a multidisciplinary sarcoma tumor board. This collaborative review by experts in surgical oncology, medical oncology, radiation oncology, pathology, and radiology is the standard of care for optimizing treatment decisions.

## Related ACR Topics and Tools

For a comprehensive overview of all clinical scenarios related to this topic, please consult the parent guide. The following tools can also assist in applying appropriateness criteria and understanding imaging studies in daily practice.

Frequently Asked Questions

Why not just use a whole-body bone scan if it has less radiation?

While a whole-body bone scan has a lower radiation dose, it only evaluates the skeleton and can be less sensitive for certain types of bone metastases (lytic or marrow-based). Critically, it provides no information on lymph node or visceral organ involvement. FDG-PET/CT offers a more comprehensive, single-session whole-body assessment of all potential metastatic sites, which is essential for accurately staging aggressive sarcomas.

Is FDG-PET/CT useful for all types of musculoskeletal tumors?

FDG-PET/CT is most useful for high-grade, metabolically active tumors like osteosarcoma, Ewing sarcoma, and most high-grade soft tissue sarcomas. Its utility is lower for certain low-grade or non-FDG-avid tumors, such as low-grade chondrosarcoma or myxoid liposarcoma, where alternative imaging strategies might be considered.

Does the patient need intravenous (IV) contrast for the CT portion of the PET/CT?

For the specific purpose of whole-body staging and localizing PET findings, IV contrast is often not necessary for the CT component. However, if there is a specific concern for metastatic disease in an organ like the liver, a contrast-enhanced diagnostic CT may be performed concurrently or as a separate follow-up study. Local institutional protocols may vary.

If the PET/CT is negative, is the patient considered cured?

No. A negative staging PET/CT indicates that there is no evidence of distant metastatic disease at the time of the scan. The patient is considered to have localized disease, but they still require definitive treatment of the primary tumor (surgery, radiation) and often systemic chemotherapy to treat potential microscopic disease and reduce the risk of future recurrence.

What about using FDG-PET/MRI for this indication?

FDG-PET/MRI is an emerging technology rated as ‘May be appropriate’ by the ACR for this scenario. It combines the metabolic data of PET with the superior soft-tissue and bone marrow contrast of MRI, and it involves less ionizing radiation than PET/CT. However, it is less widely available, more expensive, and takes longer to perform. It is a promising alternative that may see increased use in the future.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026